Renal gangliosides are involved in lead intoxication.
The biological effects of lead are well defined; however, neither the risk exposure level nor the subcellular mechanism of its action is completely clear. The present work was undertaken to investigate the effects of low level and long term lead exposure on the composition and expression of rat renal gangliosides. In order to identify ganglioside expression, frozen sections of kidneys were stained with monoclonal antibodies GMB16 (GM1 specific), GM28 (GM2 specific), AMR-10 (GM4 specific) and CDW 60 (9-O-Ac-GD3 specific). Strong reactivity was observed for GMB28, AMR-10 and CDW 60, while GMB16 developed only weak labelling in treated kidney compared with the control. The alterations in the expression of renal gangliosides observed by immunohistochemistry were accompanied by quantitative and qualitative changes in the thin layer chromatography of total gangliosides isolated from kidney tissues. Lead treatment produced a significant increase in 9-O-Ac GD3, a ganglioside involved in apoptotic processes. In agreement with this result, a significant decrease in the number of apoptotic glomerular cells was observed with the TUNEL assay. These findings lead us to suggest that alterations in renal gangliosides produced by low level lead exposure are associated with the apoptotic processes that take place in the kidney. These findings provide evidence that low level and long term lead exposure produces renal ganglioside alterations with urinary microalbumin excretion. The results suggest that lead levels within the limits of biological tolerance already cause molecular renal damage without clinical signs of toxicity.
Aguilar
Rossana Pérez
RP
Departamento de Biología del Desarrollo, Instituto Superior de Investigaciones Biológicas (INSIBIO), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina.
Genta
Susana
S
Sánchez
Sara
S
D000419:Albuminuria / Q000209:etiology / Q000378:metabolism; D000818:Animals; D017209:Apoptosis; D001835:Body Weight; D002855:Chromatography, Thin Layer; D004195:Disease Models, Animal; D004435:Eating; D005677:G(M1) Ganglioside / Q000378:metabolism; D005678:G(M2) Ganglioside / Q000378:metabolism; D005732:Gangliosides / Q000378:metabolism*; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D007668:Kidney / Q000378:metabolism* / Q000473:pathology; D007674:Kidney Diseases / Q000209:etiology* / Q000378:metabolism / Q000473:pathology; D007855:Lead Poisoning / Q000150:complications* / Q000378:metabolism / Q000473:pathology; D008297:Male; D009942:Organometallic Compounds / Q000097:blood; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
D005732:Gangliosides; D009942:Organometallic Compounds; D005678:G(M2) Ganglioside; D005677:G(M1) Ganglioside; C028253:ganglioside, GM4; C049132:9-O-acetyl-GD3 ganglioside; C008261:lead acetate